http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006101992-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A47K10-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A47K10-424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65H23-1882 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65D83-0811 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B65H23-188 |
| filingDate | 2004-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006101992-A |
| titleOfInvention | AGONIST-POLIPEPTIDE RECEPTOR FOR ZOTA AND ZONULIN |
| abstract | 1. The human zonulin receptor polypeptide agonist and the ZOT protein of the CTXφ phage Vibrio cholerae phage, said polypeptide agonist includes FCIGRL (SEQ ID NO: 4), where the length of said polypeptide is less than 100 amino acid residues. The agonist polypeptide according to claim 1, wherein said polypeptide consists of the amino acid residues FCIGRL (SEQ ID NO: 4). 3. The agonist polypeptide according to claim 1, where the specified polypeptide does not contain residues 294-298 (SEQ ID NO: 1). 4. An agonist polypeptide according to claim 1, wherein the length of said polypeptide is less than 50 amino acid residues. The agonist polypeptide according to claim 1, where the length of the specified polypeptide is less than 40 amino acid residues. An agonist polypeptide according to claim 1, wherein the length of said polypeptide is less than 30 amino acid residues. An agonist polypeptide according to claim 1, wherein the length of said polypeptide is less than 20 amino acid residues. An agonist polypeptide according to claim 1, wherein the length of said polypeptide is less than 10 amino acid residues. The agonist polypeptide according to claim 1, where the length of the specified polypeptide is less than 8 amino acid residues. A pharmaceutical composition for treating a disease, comprising a therapeutic agent for treating a disease; a polypeptide agonist according to claim 11. A pharmaceutical composition for treating a disease, comprising a therapeutic agent for treating a disease; and an agonist polypeptide according to claim 2.12. The pharmaceutical composition according to claim 10, wherein the disease is a food allergy. The pharmaceutical composition of claim 10, wherein the disease is a gastrointestinal infection. The pharmaceutical composition of claim 10, wherein the disease is an autoimmune disease. Pharmaceutical composition according to |
| priorityDate | 2003-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.